RxDoctor Payments Data

Leigha Crowell, NP

Adult Health · Baltimore, MDNPI 1033859152

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,063 of the $3,963 with a category attached, or 77.3%. 17 manufacturers reported payments, led by Abbott at 48.7% of the total. 2025 is the largest year on record at $1,943, 9.7 times the $200 reported in 2022.

$3,963in general payments, 2019–2025

Across 72 payments — averaging $55.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Daiichi Sankyo Inc.$434
  • AstraZeneca$283
  • Baxter Healthcare$217
  • Merck$200
  • Edwards Lifesciences$158
  • plus $741 from 11 others

What the payments were for

  • Consulting fees$90023%
  • Food & beverage$3,06377%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,963 in reported general payments places this provider in the 85th percentile of 542 adult health providers in Maryland.

See all adult health providers in Maryland

Medicare billing

Part B allowed, 2024
$4,754
Medicare patients
14
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan22$41,970
JardianceEmpagliflozin20$26,715
Eplerenone17$859
Gabapentin12$353
Carvedilol16$320
Metoprolol Succinate15$305
Warfarin Sodium21$269
Spironolactone24$204
Digoxin11$202
Atorvastatin Calcium14$168
Amiodarone Hcl11$149
Pantoprazole Sodium13$142
Famotidine15$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$80$41,97022 claims
Boehringer IngelheimJardiance$112$26,71520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 542 adult health providers in Maryland.

Other adult health in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →